Table 1.

The characteristics of the CML patients with COVID-19.

Patients	Gender	Age	TKI	Comorbidity
Patient 1	Male	27	Imatinib	None
Patient 2	Female	34	Imatinib	None
Patient 3	Male	37	Imatinib	None
Patient 4	Male	44	Imatinib	COPD
Patient 5	Female	47	Nilotinib	COPD
Patient 6	Female	47	Imatinib	None
Patient 7	Male	50	Dasatinib	None
Patient 8	Female	50	Imatinib	DM, HT
Patient 9	Female	52	Dasatinib	HT
Patient 10	Female	52	Nilotinib	CAD
Patient 11	Male	53	Imatinib	CKD
Patient 12	Male	60	Imatinib	DM, HT, CAD, CKD
Patient 13	Female	62	Imatinib	HT, CAD, COPD
Patient 14	Female	66	Dasatinib	DM, HT, CAD
Patient 15	Female	80	Dasatinib	HT, CAD, CVD, COPD
Patient 16	Female	87	Nilotinib	HT

CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; CKD: chronic renal disease; CVD: cerebrovascular disease; DM: diabetes mellitus; TKI: tyrosine kinase inhibitors; HT: hypertension.